High expression of Trop2 is associated with aggressive localized prostate cancer and is a candidate urinary biomarker

Sci Rep. 2024 Jan 4;14(1):486. doi: 10.1038/s41598-023-50215-z.


Distinguishing indolent from clinically significant localized prostate cancer is a major clinical challenge and influences clinical decision-making between treatment and active surveillance. The development of novel predictive biomarkers will help with risk stratification, and clinical decision-making, leading to a decrease in over or under-treatment of patients with prostate cancer. Here, we report that Trop2 is a prognostic tissue biomarker for clinically significant prostate cancer by utilizing the Canary Prostate Cancer Tissue Microarray (CPCTA) cohort composed of over 1100 patients from a multi-institutional study. We demonstrate that elevated Trop2 expression is correlated with worse clinical features including Gleason score, age, and pre-operative PSA levels. More importantly, we demonstrate that elevated Trop2 expression at radical prostatectomy predicts worse overall survival in men undergoing radical prostatectomy. Additionally, we detect shed Trop2 in urine from men with clinically significant prostate cancer. Our study identifies Trop2 as a novel tissue prognostic biomarker and a candidate non-invasive marker for prostate cancer.

MeSH terms

  • Biomarkers, Tumor
  • Humans
  • Male
  • Prognosis
  • Prostate / metabolism
  • Prostate-Specific Antigen
  • Prostatectomy
  • Prostatic Neoplasms* / diagnosis
  • Prostatic Neoplasms* / genetics
  • Prostatic Neoplasms* / surgery


  • Prostate-Specific Antigen
  • Biomarkers, Tumor